膜联蛋白A1在恶性肿瘤中的作用机制及其靶向药物研发进展综述

打开文本图片集

中图分类号：Q291 文献标志码：A 文章编号：1673-3851（2025）11-0844-10

引文格式：，膜联蛋白Al在恶性肿瘤中的作用机制及其靶向药物研发进展综述[J]．浙江理工大学学报（自然科学），2025，53（6）：844-853.

Reference Format： ZHAO Guangyu，LI Danting，YAN Zhibin. A review of the mechanism of annexin Al in malignant tumors and the progress of targeted drug developmentJ].Journal of Zhejiang Sci-Tech University2025，53（6）：84-853.

A review of the mechanism of annexin A1 in malignant tumors and the progress of targeted drug development

ZHAO Guangyu ，LI Danting ，YAN Zhibin （College of Life Sciences and Medicine， Zhejiang Sci-Tech University，Hangzhou 3lool8，China）

Abstract：As one of the leading causes of death worldwide，malignant tumors are severely restricting clinical treatment outcomes due to invasiveness and metastasis，as well as drug resistance and off-target effects caused by the tumor microenvironment. Annexin Al（ANXA1） regulates biological processes such as cell proliferation，apoptosis，and inflammation through formyl peptide receptors. In recent years， studies have found that dysregulated expression of ANXAl is closely associated with drug resistance， malignant cell transformation，and metastasis in various tumors. This article systematically reviews the biological functions of ANXA1，the regulatory mechanisms of tumor occurrence and development，its role in anti-tumor immunity，and research progress in targeted drug development，revealing its potential as a novel therapeutic target. The aim is to provide a scientific basis for the precise treatment of tumors targeting ANXA1.

Key words： annexin Al； malignant tumor; tumor drug resistance; tumor immunology; targetedtherapy

0 引言

恶性肿瘤，即癌症，由细胞恶性增殖引起，具有强侵袭性和转移性，严重威胁人类健康，现已成为全球最主要死亡原因之一。（剩余26324字）